The DOI matches its Crossref record; 213 of the 213 references it cites were found in a registry or an index.
Cannabinoids and Pain: New Insights From Old Molecules
Open accessAbstract
Cannabis has been used for medicinal purposes for thousands of years. The prohibition of cannabis in the middle of the 20th century has arrested cannabis research. In recent years there is a growing debate about the use of cannabis for medical purposes. The term 'medical cannabis' refers to physician-recommended use of the cannabis plant and its components, called cannabinoids, to treat disease or improve symptoms. Chronic pain is the most commonly cited reason for using medical cannabis. Cannabinoids act via cannabinoid receptors, but they also affect the activities of many other receptors, ion channels and enzymes. Preclinical studies in animals using both pharmacological and genetic approaches have increased our understanding of the mechanisms of cannabinoid-induced analgesia and provided therapeutical strategies for treating pain in humans. The mechanisms of the analgesic effect of cannabinoids include inhibition of the release of neurotransmitters and neuropeptides from presynaptic nerve endings, modulation of postsynaptic neuron excitability, activation of descending inhibitory pain pathways, and reduction of neural inflammation. Recent meta-analyses of clinical trials that have examined the use of medical cannabis in chronic pain present a moderate amount of evidence that cannabis/cannabinoids exhibit analgesic activity, especially in neuropathic pain. The main limitations of these studies are short treatment duration, small numbers of patients, heterogeneous patient populations, examination of different cannabinoids, different doses, the use of different efficacy endpoints, as well as modest observable effects. Adverse effects in the short-term medical use of cannabis are generally mild to moderate, well tolerated and transient. However, there are scant data regarding the long-term safety of medical cannabis use. Larger well-designed studies of longer duration are mandatory to determine the long-term efficacy and long-term safety of cannabis/cannabinoids and to provide definitive answers to physicians and patients regarding the risk and benefits of its use in the treatment of pain. In conclusion, the evidence from current research supports the use of medical cannabis in the treatment of chronic pain in adults. Careful follow-up and monitoring of patients using cannabis/cannabinoids are mandatory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–213 of 213
Prescribing smoked cannabis for chronic noncancer pain: preliminary recommendations.
Kahan, M., Srivastava, A., Spithoff, S. M., & Bromley, L. A. (2014) · Europe PMC (PubMed Central) · Cited by 45
Legalization of Medical Marijuana and Incidence of Opioid Mortality
Hayes, M. J., & Brown, M. S. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.2716 · Cited by 44
Howard, P. D., Twycross, R., Shuster, J. L., Mihalyo, M., & Wilcock, A. (2013) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2013.05.002 · Cited by 35
Romano, M. R., & Lograno, M. D. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.02.049 · Cited by 32
Zádor, F., & Wollemann, M. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.015 · Cited by 31
Lessons from the fatal French study BIA-10-2474
Moore, N. D. (2016) · BMJ · doi:10.1136/bmj.i2727 · Cited by 30
TRPV1–FAAH–COX: The Couples Game in Pain Treatment
Aiello, F., Carullo, G., Badolato, M., & Brizzi, A. (2016) · ChemMedChem · doi:10.1002/cmdc.201600111 · Cited by 30
Öz, M., Kury, L. A., Keun-Hang, S. Y., Mahgoub, M., & Galadari, S. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.03.010 · Cited by 24
Cannabinoids for chronic neuropathic pain
Mücke, M., Phillips, T., Radbruch, L., Petzke, F. W., & Häuser, W. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012182 · Cited by 18
Inhibition of 5-HT3 receptors-activated currents by cannabinoids in rat trigeminal ganglion neurons
Shi, B., Yang, R., Wang, X., Liu, H., Zou, L. B., Xiao-qun, H., Wu, J., Zou, A., & Liu, L. (2012) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-012-0047-1 · Cited by 15
Vuckovic, S. M., Tomic´, M. A., Stepanović-Petrović, R. M., Ugrešić, N. D., Prostran, M. S., & Bošković, B. (2006) · Journal of Pharmacological Sciences · doi:10.1254/jphs.sce05003x · Cited by 15
Self-citationCoanalgesics for Chronic Pain Therapy: A Narrative Review
Bair, M. J., & Sanderson, T. R. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.11.2504 · Cited by 15
Arylboronic acids as dual-action FAAH and TRPV1 ligands
Morera, E., Marzo, V. D., Monti, L., Allarà, M., Moriello, A. S., Nalli, M., Ortar, G., & PETROCELLIS, L. D. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.01.071 · Cited by 15
Cited by
The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases
Lowe, H., Toyang, N., Steele, B., Bryant, J., & Ngwa, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179472 · Cited by 303
Cardiovascular Effects of Cannabinoids
Wang, A., Dey, S., Subhan, S., Patel, J., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000566 · Cited by 6
Cannabis-Based Products for Chronic Pain: An Updated Systematic Review
Chou, R., Fu, R., Ahmed, A. Y., & Morasco, B. J. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-03152 · Cited by 4
Metadata
- Authors
- Vučković, S., Srebro, D., Vujović, K. S., Vučetić, Č., & Prostran, M.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2018-11-13
- Volume
- 9
- Pages
- 1259-1259
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2901552564
- Cited by
- 376
- References
- 213
- FWCI
- 15.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.